Clinical Trial Update: Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10% [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating intravenous immunoglobulin (IGIV-C) 10% to improve transplant options for highly sensitized recipients with chronic kidney failure wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• IGIV-C 10% Intravenous Immunoglobulin (intravenous immunoglobulin (IVIG), 10% solution)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Kidney Failure, Chronic | Phase 2 | Status: TERMINATED